Honz Pharmaceutical Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Jiangtao Hong

Chief executive officer

CN¥324.5k

Total compensation

CEO salary percentage	n/a
CEO tenure	4.4yrs
CEO ownership	0.5%
Management average tenure	no data
Board average tenure	4.4yrs

Recent management updates

Recent updates

CEO

Jiangtao Hong (53 yo)

4.4yrs

Tenure

CN¥324,500

Compensation

Mr. Jiangtao Hong has been President at Honz Pharmaceutical Co., Ltd. since December 19, 2019 and served as its Vice President.

Board Members

Name	Position	Tenure	Compensation	Ownership
Liping Hong	Vice Chairman & VP	16.4yrs	CN¥339.50k	0.17% CN¥ 3.6m
Jiangyou Hong	Chairman	16.4yrs	CN¥460.00k	1.71% CN¥ 35.9m
Qinghe Wu	Independent Director	1.4yrs	CN¥3.80k	no data
Huan Xue Zheng	Independent Director	1.4yrs	CN¥3.80k	no data
Youquan Li	Non-Independent Director	4.4yrs	CN¥180.00k	no data
Dongxiong Hong	Director	1.4yrs	no data	no data
Chunying Wang	Non-Employee Supervisor	4.4yrs	no data	0.00011% CN¥ 2.3k
Jicheng Zhang	Independent Director	4.4yrs	CN¥90.00k	no data
Mengke Sun	Non-Employee Supervisor	1.4yrs	no data	no data

4.4yrs

Average Tenure

54yo

Average Age

Experienced Board: 300086's board of directors are considered experienced (4.4 years average tenure).

Honz Pharmaceutical Management

Management criteria checks 3/4

Key information

Recent management updates

Honz Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023

Honz Pharmaceutical Co., Ltd. Announces Directorate Appointments

High number of new and inexperienced directors

Honz Pharmaceutical Co., Ltd., Annual General Meeting, Jun 30, 2022

High number of new and inexperienced directors

Recent updates

First quarter 2024 earnings released: CN¥0.10 loss per share (vs CN¥0.034 profit in 1Q 2023)

Honz Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 29, 2024

New minor risk - Share price stability

Honz Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024

Third quarter 2023 earnings released: CN¥0.082 loss per share (vs CN¥0.049 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.002 (vs CN¥0.092 loss in 2Q 2022)

Honz Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023

Full year 2022 earnings released: CN¥0.42 loss per share (vs CN¥0.024 profit in FY 2021)

Honz Pharmaceutical Co., Ltd. Announces Directorate Appointments

High number of new and inexperienced directors

Third quarter 2022 earnings released: CN¥0.049 loss per share (vs CN¥0.036 profit in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.092 loss per share (vs CN¥0.062 loss in 2Q 2021)

Honz Pharmaceutical Co., Ltd., Annual General Meeting, Jun 30, 2022

First quarter 2022 earnings released: CN¥0.10 loss per share (vs CN¥0.066 loss in 1Q 2021)

High number of new and inexperienced directors

Full year 2021 earnings released: EPS: CN¥0.024 (vs CN¥0.021 in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.036 (vs CN¥0.012 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.062 loss per share (vs CN¥0.042 profit in 2Q 2020)

Honz Pharmaceutical Co., Ltd. Announces Final Profit Distribution Proposal for 2020

Full year 2020 earnings released: EPS CN¥0.021 (vs CN¥0.059 loss in FY 2019)

New 90-day low: CN¥4.85

New 90-day low: CN¥5.87

New 90-day low: CN¥6.07

New 90-day low: CN¥6.38

Honz Pharmaceutical Co., Ltd. announced that it expects to receive CNY 634.6 million in funding

Third quarter earnings released

Earnings released

Honz Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

New 90-day high - CN¥8.26

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age